Is Secukinumab included in medical insurance?

The original drug Secukinumab (Secukinumab) has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. The reimbursement ratio is different in different regions, and the price after reimbursement may vary. The price of each box of 150mg/ML is around RMB 1,000.

Secukinumab is a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A). It has been proven to have significant efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis, showing rapid onset of action and sustained response as well as a good safety profile. Blocking key mediators of immunity may increase the risk of opportunistic infections. Secukinumabinhibits interleukin17A, a member of the cytokine family, which is produced primarily by inflammatory helper T cells 17. IL-17A is upregulated in the serum of patients with psoriasis and in the synovial fluid of patients with psoriatic arthritis and promotes inflammation when it binds to the interleukin-17 receptor, which is expressed in various cell types, including keratinocytes in the skin.

SecukinumabThe original drug has also been launched overseas. The specifications of the Turkish original versionThe price per box of 150mg/ML is about 1,500 yuan, and the European version is 150mg/ML. *The price of each box of 2 pills is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there are no generic secukinumab drugs on the market.